Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...
- SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - -...
- Two posters reporting activity for SRA737 with PARPi (in CCNE1-driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this...
View all news releases
Next Generation DDR Therapeutics - Q2 2018
View All Presentations
Location: Four Seasons Hotel Vancouver
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts